Susquehanna International Group’s Aurinia Pharmaceuticals AUPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.07M | Sell |
72,400
-65,200
| -47% | -$953K | ﹤0.01% | 7706 |
|
|
2025
Q4 | $2.19M | Sell |
137,600
-61,000
| -31% | -$865K | ﹤0.01% | 5461 |
|
|
2025
Q3 | $2.19M | Buy |
198,600
+53,000
| +36% | +$579K | ﹤0.01% | 5576 |
|
|
2025
Q2 | $1.23M | Sell |
145,600
-23,700
| -14% | -$190K | ﹤0.01% | 6901 |
|
|
2025
Q1 | $1.36M | Sell |
169,300
-42,900
| -20% | -$348K | ﹤0.01% | 6466 |
|
|
2024
Q4 | $1.91M | Sell |
212,200
-369,900
| -64% | -$3.02M | ﹤0.01% | 5425 |
|
|
2024
Q3 | $4.27M | Buy |
582,100
+377,000
| +184% | +$2.34M | ﹤0.01% | 3864 |
|
|
2024
Q2 | $1.17M | Sell |
205,100
-276,100
| -57% | -$1.45M | ﹤0.01% | 6207 |
|
|
2024
Q1 | $2.41M | Buy |
481,200
+137,500
| +40% | +$933K | ﹤0.01% | 4936 |
|
|
2023
Q4 | $3.09M | Buy |
343,700
+69,000
| +25% | +$568K | ﹤0.01% | 4520 |
|
|
2023
Q3 | $2.13M | Sell |
274,700
-353,600
| -56% | -$3.46M | ﹤0.01% | 4995 |
|
|
2023
Q2 | $6.08M | Sell |
628,300
-90,400
| -13% | -$938K | ﹤0.01% | 3209 |
|
|
2023
Q1 | $7.88M | Buy |
718,700
+41,400
| +6% | +$365K | ﹤0.01% | 2797 |
|
|
2022
Q4 | $2.93M | Sell |
677,300
-78,300
| -10% | -$454K | ﹤0.01% | 4053 |
|
|
2022
Q3 | $5.68M | Sell |
755,600
-384,400
| -34% | -$3.33M | ﹤0.01% | 2957 |
|
|
2022
Q2 | $11.5M | Sell |
1,140,000
-278,800
| -20% | -$3.12M | ﹤0.01% | 2030 |
|
|
2022
Q1 | $17.6M | Sell |
1,418,800
-328,500
| -19% | -$5.08M | ﹤0.01% | 1861 |
|
|
2021
Q4 | $40M | Sell |
1,747,300
-47,500
| -3% | -$1.13M | 0.01% | 1265 |
|
|
2021
Q3 | $39.7M | Buy |
1,794,800
+238,900
| +15% | +$3.79M | 0.01% | 1324 |
|
|
2021
Q2 | $20.2M | Buy |
1,555,900
+462,400
| +42% | +$5.89M | ﹤0.01% | 2025 |
|
|
2021
Q1 | $14.2M | Sell |
1,093,500
-9,700
| -0.9% | -$141K | ﹤0.01% | 2299 |
|
|
2020
Q4 | $15.3M | Buy |
1,103,200
+376,600
| +52% | +$5.48M | ﹤0.01% | 2020 |
|
|
2020
Q3 | $10.7M | Buy |
726,600
+280,800
| +63% | +$4.07M | ﹤0.01% | 2093 |
|
|
2020
Q2 | $7.24M | Buy |
445,800
+40,900
| +10% | +$655K | ﹤0.01% | 2531 |
|
|
2020
Q1 | $5.88M | Sell |
404,900
-135,400
| -25% | -$2.39M | ﹤0.01% | 2371 |
|
|
2019
Q4 | $10.9M | Sell |
540,300
-200,900
| -27% | -$1.85M | ﹤0.01% | 1997 |
|
|
2019
Q3 | $3.96M | Buy |
741,200
+290,400
| +64% | +$1.76M | ﹤0.01% | 3051 |
|
|
2019
Q2 | $2.97M | Buy |
450,800
+14,800
| +3% | +$94.3K | ﹤0.01% | 3471 |
|
|
2019
Q1 | $2.83M | Buy |
436,000
+273,900
| +169% | +$1.82M | ﹤0.01% | 3212 |
|
|
2018
Q4 | $1.11M | Sell |
162,100
-17,600
| -10% | -$101K | ﹤0.01% | 4489 |
|
|
2018
Q3 | $1.19M | Sell |
179,700
-51,200
| -22% | -$287K | ﹤0.01% | 4883 |
|
|
2018
Q2 | $1.3M | Sell |
230,900
-14,900
| -6% | -$83.1K | ﹤0.01% | 4811 |
|
|
2018
Q1 | $1.28M | Buy |
245,800
+74,700
| +44% | +$400K | ﹤0.01% | 4741 |
|
|
2017
Q4 | $775K | Sell |
171,100
-34,300
| -17% | -$190K | ﹤0.01% | 5745 |
|
|
2017
Q3 | $1.29M | Sell |
205,400
-34,900
| -15% | -$220K | ﹤0.01% | 4788 |
|
|
2017
Q2 | $1.47M | Sell |
240,300
-132,500
| -36% | -$893K | ﹤0.01% | 4467 |
|
|
2017
Q1 | $2.74M | Buy |
372,800
+182,200
| +96% | +$842K | ﹤0.01% | 3180 |
|
|
2016
Q4 | $400K | Buy |
+190,600
| New | +$613K | ﹤0.01% | 7428 |
|
Other funds holding AUPH
TCM
NMC
Susquehanna International Group's AUPH Position: Q1 2026 in Review
Susquehanna International Group increased its Aurinia Pharmaceuticals (AUPH) stake by 60% in Q1 2026, buying an estimated $221K and bringing the position to 40,537 shares worth $601K. The position accounts for ﹤0.01% of the portfolio, ranked #9198.
Susquehanna International Group first reported a position in AUPH in Q4 2016 and has held it in 37 quarters since. The position peaked at $84.6M in Q3 2021. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.
- Susquehanna International Group held 40,537 shares of Aurinia Pharmaceuticals worth $601K as of Q1 2026.
- Susquehanna International Group bought 15,153 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $221K.
- Aurinia Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9198 holding.
- Susquehanna International Group first reported a position in Aurinia Pharmaceuticals in Q4 2016 and has held it in 37 quarters since.
- Susquehanna International Group's Aurinia Pharmaceuticals position peaked at $84.6M in Q3 2021.
- 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.